Evaluation of antitumor efficacy of folate-poly(2-ethyl-2-oxazoline)-distearoyl phosphatidyl ethanolamine based liposome

References

• Barenholz Y. 2012. Doxil®-the first FDA-approved nano-drug: lessons learned. J Control Release. 160(2):117–134.
   PubMed Web of Science ®Google Scholar
• Bauer M, Lautenschlaeger C, Kempe K, Tauhardt L, Schubert US, Fischer D. 2012. Poly(2-ethyl-2-oxazoline) as alternative for the stealth polymer poly(ethylene glycol): comparison of in vitro cytotoxicity and hemocompatibility. Macromol Biosci. 12(7):986–998.
   PubMed Web of Science ®Google Scholar
• D’Souza AA, Shegokar R. 2016. Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications. Expert Opin Drug Deliv. 13(9):1257–1275.
   PubMed Web of Science ®Google Scholar
• Gaertner FC, Luxenhofer R, Blechert B, Jordan R, Essler M. 2007. Synthesis, biodistribution and excretion of radiolabeled poly(2-alkyl-2-oxazoline)s. J Control Release. 119(3):291–300.
   PubMed Web of Science ®Google Scholar
• Hadjesfandiari N, Parambath A. 2018. Stealth coatings for nanoparticles: polyethylene glycol alternatives. In: Parambath A, editor. Engineering of biomaterials for drug delivery systems: beyond polyethylene glycol. Sawston (UK): Woodhead Publishing; p. 345–361.
   Google Scholar
• Han S, Sun R, Su H, Lv J, Xu H, Zhang D, Fu Y. 2019. Delivery of docetaxel using pH-sensitive liposomes based on D-alpha-tocopheryl poly(2-ethyl-2-oxazoline) succinate: comparison with PEGylated liposomes. Asian J Pharm Sci. 14(4):391–404.
   PubMed Web of Science ®Google Scholar
• Jing F, Li D, Xu W, Liu Y, Wang K, Sui Z. 2014. Transferrin- and folate-modified, double-targeted nanocarriers for gene delivery. Pharm Biol. 52(5):570–574.
   PubMed Web of Science ®Google Scholar
• Khutoryanskiy VV. 2018. Beyond PEGylation: alternative surface-modification of nanoparticles with mucus-inert biomaterials. Adv Drug Deliv Rev. 124:140–149.
   PubMed Web of Science ®Google Scholar
• Lorson T, Lubtow MM, Wegener E, Haider MS, Borova S, Nahm D, Jordan R, Sokolski-Papkov M, Kabanov AV, Luxenhofer R. 2018. Poly(2-oxazoline)s based biomaterials: a comprehensive and critical update. Biomaterials. 178:204–280.
   PubMed Web of Science ®Google Scholar
• Lu Y, Wu J, Wu J, Gonit M, Yang X, Lee A, Xiang G, Li H, Liu S, Marcucci G, et al. 2007. Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells. Mol Pharm. 4(5):707–712.
   PubMed Web of Science ®Google Scholar
• Ma Y, Yang Q, Wang L, Zhou X, Zhao Y, Deng Y. 2012. Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats. Eur J Pharm Sci. 45(5):539–545.
   PubMed Web of Science ®Google Scholar
• Mohamed M, Abu Lila AS, Shimizu T, Alaaeldin E, Hussein A, Sarhan HA, Szebeni J, Ishida T. 2019. PEGylated liposomes: immunological responses. Sci Technol Adv Mater. 20(1):710–724.
   PubMed Web of Science ®Google Scholar
• Nagao A, Abu Lila AS, Ishida T, Kiwada H. 2013. Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application. Int J Pharm. 441(1–2):395–401.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Abu Lila AS, Fujita R, Awata M, Kawanishi M, Hashimoto Y, Okuhira K, Ishima Y, Ishida T. 2018. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes. Eur J Pharm Biopharm. 127:142–149.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ichihara M, Hyodo K, Yamamoto E, Ishida T, Kiwada H, Ishihara H, Kikuchi H. 2012. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs. Int J Pharm. 436(1–2):636–643.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ichihara M, Hyodo K, Yamamoto E, Ishida T, Kiwada H, Kikuchi H, Ishihara H. 2014. Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin. Int J Pharm. 476(1–2):205–212.
   PubMed Web of Science ®Google Scholar
• Wang C, Cheng X, Su Y, Pei Y, Song Y, Jiao J, Huang Z, Ma Y, Dong Y, Yao Y, et al. 2015. Accelerated blood clearance phenomenon upon cross-administration of PEGylated nanocarriers in beagle dogs. Int J Nanomedicine. 10:3533–3545.
   PubMed Web of Science ®Google Scholar
• Wang CH, Hsiue GH. 2003. New amphiphilic poly(2-ethyl-2-oxazoline)/ poly(L-lactide) triblock copolymers. Biomacromolecules. 4(6):1487–1490.
   PubMed Web of Science ®Google Scholar
• Wang CH, Wang CH, Hsiue GH. 2005. Polymeric micelles with a pH-responsive structure as intracellular drug carriers. J Control Release. 108(1):140–149.
   PubMed Web of Science ®Google Scholar
• Wang F, Ye X, Wu Y, Wang H, Sheng C, Peng D, Chen W. 2019. Time interval of two injections and first-dose dependent of accelerated blood clearance phenomenon induced by PEGylated liposomal gambogenic acid: the contribution of PEG-specific IgM. J Pharm Sci. 108(1):641–651.
   PubMed Web of Science ®Google Scholar
• Wang X, Li X, Li Y, Zhou Y, Fan C, Li W, Ma S, Fan Y, Huang Y, Li N, et al. 2011. Synthesis, characterization and biocompatibility of poly(2-ethyl-2-oxazoline)-poly(D,L-lactide)-poly(2-ethyl-2-oxazoline) hydrogels. Acta Biomater. 7(12):4149–4159.
   PubMed Web of Science ®Google Scholar
• Xia G, An Z, Wang Y, Zhao C, Li M, Li Z, Ma J. 2013. Synthesis of a novel polymeric material folate-poly(2-ethyl-2-oxazoline)-distearoyl phosphatidyl ethanolamine tri-block polymer for dual receptor and pH-sensitive targeting liposome. Chem Pharm Bull. 61(4):390–398.
   PubMed Web of Science ®Google Scholar
• Xu H, Zhang W, Li Y, Ye FF, Yin PP, Yu X, Hu MN, Fu YS, Wang C, Shang de J. 2014. The bifunctional liposomes constructed by poly(2-ethyl-oxazoline)-cholesteryl methyl carbonate: an effectual approach to enhance liposomal circulation time, pH-sensitivity and endosomal escape. Pharm Res. 31(11):3038–3050.
   PubMed Web of Science ®Google Scholar
• Yan Y, Qi XR. 2008. [Preparation and properties of folate receptor-targeted cationic liposomes]. Yao Xue Xue Bao. 43(11):1134–1139. Chinese.
   PubMedGoogle Scholar
• Yang Y, He L, Liu Y, Xia S, Fang A, Xie Y, Gan L, He Z, Tan X, Jiang C, et al. 2016. Promising nanocarriers for PEDF gene targeting delivery to cervical cancer cells mediated by the over-expressing FRα. Sci Rep. 6:32427.
   PubMed Web of Science ®Google Scholar
• Zalipsky S, Hansen CB, Oaks JM, Allen TM. 1996. Evaluation of blood clearance rates and biodistribution of poly(2-oxazoline)-grafted liposomes. J Pharm Sci. 85(2):133–137.
   PubMed Web of Science ®Google Scholar
• Zhang P, Sun F, Liu S, Jiang S. 2016. Anti-PEG antibodies in the clinic: current issues and beyond PEGylation. J Control Release. 244:184–193.
   PubMed Web of Science ®Google Scholar